A5006549117- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Hypoxia, and Metabolism
- Meningioma and schwannoma management
- Neuroblastoma Research and Treatments
- Cancer Treatment and Pharmacology
- Cancer-related cognitive impairment studies
- Autoimmune Neurological Disorders and Treatments
- Neurofibromatosis and Schwannoma Cases
- Vascular Malformations Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Ubiquitin and proteasome pathways
- Epigenetics and DNA Methylation
- Histone Deacetylase Inhibitors Research
- Melanoma and MAPK Pathways
- Ferroptosis and cancer prognosis
- CNS Lymphoma Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer Mechanisms and Therapy
- Management of metastatic bone disease
- Cancer Research and Treatments
- TGF-β signaling in diseases
- Medical Imaging Techniques and Applications
- Advanced Radiotherapy Techniques
University of Toronto
2016-2025
Princess Margaret Cancer Centre
2015-2024
University Health Network
2015-2024
Princess Margaret Hospital
2005-2024
Toronto General Hospital
1999-2024
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
2024
Toronto Public Health
2024
Western University
2004-2023
Deleted Institution
2023
National Institute of Neurological Disorders and Stroke
2023
Glioblastoma, the most common primary brain tumor in adults, is usually rapidly fatal. The current standard of care for newly diagnosed glioblastoma surgical resection to extent feasible, followed by adjuvant radiotherapy. In this trial we compared radiotherapy alone with plus temozolomide, given concomitantly and after radiotherapy, terms efficacy safety.Patients diagnosed, histologically confirmed were randomly assigned receive (fractionated focal irradiation daily fractions 2 Gy 5 days...
Epigenetic silencing of the MGMT (O6-methylguanine–DNA methyltransferase) DNA-repair gene by promoter methylation compromises DNA repair and has been associated with longer survival in patients glioblastoma who receive alkylating agents.
Abstract Objective To report the autoantigens of a new category treatment‐responsive paraneoplastic encephalitis. Methods Analysis clinical features, neuropathological findings, tumors, and serum/cerebrospinal fluid antibodies using rat tissue, neuronal cultures, HEK293 cells expressing subunits N ‐methyl‐ D ‐aspartate receptor (NMDAR). Results Twelve women (14–44 years) developed prominent psychiatric symptoms, amnesia, seizures, frequent dyskinesias, autonomic dysfunction, decreased level...
Standard therapy for newly diagnosed glioblastoma is radiotherapy plus temozolomide. In this phase 3 study, we evaluated the effect of addition bevacizumab to radiotherapy-temozolomide treatment glioblastoma.We randomly assigned patients with supratentorial receive intravenous (10 mg per kilogram body weight every 2 weeks) or placebo, (2 Gy 5 days a week; maximum, 60 Gy) and oral temozolomide (75 square meter body-surface area day) 6 weeks. After 28-day break, maintenance intravenously (150...
Glioblastoma is associated with a poor prognosis in the elderly. Survival has been shown to increase among patients 70 years of age or younger when temozolomide chemotherapy added standard radiotherapy (60 Gy over period 6 weeks). In elderly patients, more convenient shorter courses are commonly used, but benefit adding course unknown.We conducted trial involving 65 older newly diagnosed glioblastoma. Patients were randomly assigned receive either alone (40 15 fractions) concomitant and...
Abstract We report four young women who developed acute psychiatric symptoms, seizures, memory deficits, decreased level of consciousness, and central hypoventilation associated with ovarian teratoma (OT) cerebrospinal fluid (CSF) inflammatory abnormalities. Three patients recovered treatment the tumor or immunosuppression one died disorder. Five other OT a similar syndrome response to have been reported. Our patients' serum CSF showed immunolabeling antigens that were expressed at...
Purpose A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recentin in Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of cediranib, an oral pan–vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, either as monotherapy or combination with lomustine versus patients recurrent glioblastoma. Patients Methods (N = 325) glioblastoma who previously received radiation temozolomide were randomly assigned...
The European Organisation for Research and Treatment of Cancer National Institute Canada trial on temozolomide (TMZ) radiotherapy (RT) in glioblastoma (GBM) has demonstrated that the combination TMZ RT conferred a significant meaningful survival advantage compared with alone. We evaluated this whether recursive partitioning analysis (RPA) retains its overall prognostic value what benefit combined modality is each RPA class.Five hundred seventy-three patients newly diagnosed GBM were randomly...
This phase III open-label study compared the efficacy and safety of enzastaurin versus lomustine in patients with recurrent glioblastoma (WHO grade 4).Patients were randomly assigned 2:1 to receive 6-week cycles 500 mg/d (1,125-mg loading dose, day 1) or (100 130 mg/m(2), 1). Assuming a 45% improvement progression-free survival (PFS), 397 required provide 80% power achieve statistical significance at one-sided level .025.Enrollment was terminated 266 (enzastaurin, n = 174; lomustine, 92)...
Purpose Concomitant temozolomide (TMZ)/radiotherapy followed by adjuvant TMZ has increased survival in patients with glioblastoma multiforme (GBM). However, few options are effective for who experience treatment failure. We conducted a multicenter, phase II study to assess the efficacy and safety of continuous dose-intense recurrent GBM. Patients Methods malignant glioma at progression after standard 150 200 mg/m 2 × 5 days 28-day cycle three or more cycles were stratified tumor type...
Isocitrate dehydrogenase (IDH)-mutant grade 2 gliomas are malignant brain tumors that cause considerable disability and premature death. Vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 IDH2 enzymes, showed preliminary activity in IDH-mutant gliomas.
Aberrant Notch signaling has been implicated in the pathogenesis of many human cancers. MK-0752 is a potent, oral inhibitor γ-secretase, an enzyme required for pathway activation. Safety, maximum-tolerated dose, pharmacokinetics (PKs), pharmacodynamics, and preliminary antitumor efficacy were assessed phase I study MK-0752.MK-0752 was administered three different schedules to patients with advanced solid tumors. Hair follicles collected at higher dose levels assess gene signature...
This analysis was performed to assess whether antiepileptic drugs (AEDs) modulate the effectiveness of temozolomide radiochemotherapy in patients with newly diagnosed glioblastoma.The European Organization for Research and Treatment Cancer (EORTC) 26981-22981/National Institute Canada (NCIC) CE.3 clinical trial database radiotherapy (RT) or without (TMZ) glioblastoma examined impact interaction between AED use chemoradiotherapy on survival. Data were adjusted known prognostic factors.When...
The AVAglio (Avastin in Glioblastoma) and RTOG-0825 randomized, placebo-controlled phase III trials newly diagnosed glioblastoma reported prolonged progression-free survival (PFS), but not overall (OS), with the addition of bevacizumab to radiotherapy plus temozolomide. To establish whether certain patient subgroups derived an OS benefit from first-line standard-of-care therapy, patients were retrospectively evaluated for molecular subtype, efficacy was assessed each subgroup.A total 349...
Abstract Immune-mediated anti-tumoral responses, elicited by oncolytic viruses and augmented with checkpoint inhibition, may be an effective treatment approach for glioblastoma. Here in this multicenter phase 1/2 study we evaluated the combination of intratumoral delivery virus DNX-2401 followed intravenous anti-PD-1 antibody pembrolizumab recurrent glioblastoma, first a dose-escalation then dose-expansion phase, 49 patients. The primary endpoints were overall safety objective response rate....
PURPOSE Anti-Hu antibodies (HuAb) recognize antigens expressed by neurons and small-cell lung cancer (SCLC). High titers of HuAb were initially reported in serum from patients with paraneoplastic encephalomyelitis/sensory neuropathy (PEM/SN) SCLC. Preliminary studies have indicated that some SCLC without PEM/SN harbor low titer their serum, the these may grow more indolently. Based on observations, we conducted a multicenter prospective study to determine incidence prognostic implications...
Several cancers, especially lung, ovarian and breast, can cause paraneoplastic cerebellar degeneration. The presence of different antineuronal antibodies associated with cancers degeneration suggests that several immunological mechanisms may result in the same neurological disorder. In patients small-cell lung cancer, occur or without Hu (HuAb), indicating tumour develop by mechanisms. Furthermore, sometimes occurs association Lambert-Eaton myasthenic syndrome. order to try understand...